Want to see HK:1846 full AI Analyst Report?
Top Page
EuroEyes International Eye Clinic Limited
(1846)
Select Model
Select Model
Rating:66Neutral
Price Target:
HK$2.50
▼(-16.67% Downside)
Action:Reiterated
Date:08/06/26
Overall score reflects solid balance-sheet support and healthy cash generation, offset by a notable recent drop in profitability/ROE and higher debt. Technicals are neutral with longer-term trend pressure, while valuation is reasonable but not compelling enough to fully outweigh the earnings deterioration.
Positive Factors
Revenue Growth
The return to revenue growth indicates renewed demand for the company’s ophthalmology services after a broadly flat 2024. Continued top-line expansion can improve clinic utilization, support investment in care capacity, and provide a foundation for rebuilding earnings over the next several quarters.
Negative Factors
Profitability Decline
The decline in net income despite higher revenue signals weaker earnings conversion and suggests margin compression or increased costs. Unless profitability improves, revenue growth will generate less shareholder value, constrain reinvestment capacity, and keep earnings quality below the stronger 2021–2023 period.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Growth
The return to revenue growth indicates renewed demand for the company’s ophthalmology services after a broadly flat 2024. Continued top-line expansion can improve clinic utilization, support investment in care capacity, and provide a foundation for rebuilding earnings over the next several quarters.
Read all positive factors
EuroEyes International Eye Clinic Limited (1846) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$703.50M
Dividend Yield2%
Average Volume (3M)22.62K
Price to Earnings (P/E)285.7
Beta (1Y)0.19
Revenue Growth20.54%
EPS Growth-96.74%
CountryHK
Employees409
SectorHealthcare
Sector Strength45
IndustryMedical - Care Facilities
Share Statistics
EPS (TTM)<0.01
Shares Outstanding320,706,000
10 Day Avg. Volume31,100
30 Day Avg. Volume22,621
Financial Highlights & Ratios
PEG Ratio-0.56
Price to Book (P/B)0.78
Price to Sales (P/S)1.22
P/FCF Ratio6.56
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
EuroEyes International Eye Clinic Limited Business Overview & Revenue Model
Company Description
EuroEyes International Eye Clinic Limited provides vision correction services in Germany, the People’s Republic of China, Denmark, and the United Kingdom. The company offers laser eye surgery in various options, including SMILE Pro, Femto-Lasik, P...
How the Company Makes Money
EuroEyes primarily generates revenue by providing paid, patient-facing ophthalmology services through its clinics. Key revenue streams typically include: (1) procedure fees from elective vision correction treatments, where patients pay for surgica...
EuroEyes International Eye Clinic Limited Financial Statement Overview
Summary
Income Statement
63
Positive
Balance Sheet
74
Positive
Cash Flow
71
Positive
| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 873.25M | 796.04M | 715.68M | 714.29M | 610.29M | 632.93M |
| Gross Profit | 332.13M | 324.33M | 286.59M | 335.52M | 270.84M | 312.55M |
| EBITDA | 197.82M | 244.19M | 216.93M | 292.10M | 220.44M | 278.80M |
| Net Income | 2.49M | 54.45M | 82.28M | 131.24M | 89.47M | 133.56M |
Balance Sheet | ||||||
| Total Assets | 1.83B | 1.95B | 1.60B | 1.75B | 1.54B | 1.37B |
| Cash, Cash Equivalents and Short-Term Investments | 607.70M | 696.70M | 653.23M | 720.38M | 779.57M | 861.58M |
| Total Debt | 387.46M | 410.19M | 319.29M | 384.26M | 290.41M | 221.48M |
| Total Liabilities | 574.75M | 667.78M | 473.72M | 588.09M | 497.95M | 328.55M |
| Stockholders Equity | 1.22B | 1.25B | 1.09B | 1.13B | 1.01B | 1.01B |
Cash Flow | ||||||
| Free Cash Flow | 138.71M | 148.11M | 117.41M | 102.30M | 152.46M | 228.71M |
| Operating Cash Flow | 183.17M | 193.75M | 197.75M | 191.85M | 208.76M | 273.26M |
| Investing Cash Flow | -196.38M | -113.47M | -83.83M | -180.28M | -131.81M | -59.90M |
| Financing Cash Flow | -106.57M | -115.97M | -136.82M | -102.76M | -102.22M | -69.18M |
EuroEyes International Eye Clinic Limited Technical Analysis
Negative
3.00
Price Trends
2.40
Negative
2.44
Negative
2.61
Negative
Market Momentum
-0.06
Positive
34.04
Neutral
10.59
Positive
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1846, the sentiment is Negative. The current price of 3 is above the 20-day moving average (MA) of 2.39, above the 50-day MA of 2.40, and above the 200-day MA of 2.61, indicating a bearish trend. The MACD of -0.06 indicates Positive momentum. The RSI at 34.04 is Neutral, neither overbought nor oversold. The STOCH value of 10.59 is Positive, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1846.
EuroEyes International Eye Clinic Limited Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
74 Outperform | HK$1.66B | 8.34 | 6.97% | 10.27% | 3.85% | -1.23% | |
67 Neutral | HK$1.05B | 10.10 | 5.57% | 2.29% | 4.75% | ― | |
66 Neutral | HK$703.50M | 285.71 | 0.20% | 2.00% | 20.54% | -96.74% | |
52 Neutral | HK$1.10B | 78.10 | 0.48% | 1.10% | -3.26% | ― | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | HK$292.35M | -3.79 | -10.76% | 9.04% | -1.37% | -334.69% | |
50 Neutral | HK$467.79M | -143.62 | -0.41% | ― | 3.16% | -101.02% |
* Healthcare Sector Average
HK:1846
EuroEyes International Eye Clinic Limited
2.20
-1.13
-33.97%
HK:2219
Chaoju Eye Care Holdings Ltd.
2.36
0.03
1.20%
HK:3309
C-MER Eye Care Holdings Limited
0.85
-0.91
-51.81%
HK:3869
Hospital Corporation of China Ltd
3.39
-2.61
-43.49%
HK:3886
Town Health International Medical Group Ltd.
0.16
-0.11
-40.07%
HK:0722
UMP Healthcare Holdings Limited
0.37
-0.08
-17.61%
EuroEyes International Eye Clinic Limited Corporate Events
EuroEyes Restructures Senior Leadership as CFO Bracklo Moves to Non-Executive Role
Oct 30, 2026
EuroEyes International Eye Clinic Limited has announced that Chief Financial Officer Marcus Huascar Bracklo will resign from his CFO role and cease to serve as the company’s authorised representative under Hong Kong listing rules, effective ...
EuroEyes Sets Board and Committee Roles Effective End-October 2026
Oct 30, 2026
EuroEyes International Eye Clinic Limited has confirmed the composition of its board of directors effective 31 October 2026, comprising four executive directors and three independent non-executive directors, with Dr. Jørn Slot Jørgensen ...
EuroEyes Publishes Unaudited Interim Results for First Half of 2026
Aug 31, 2026
EuroEyes International Eye Clinic Limited has released its unaudited interim results for the six months ended 30 June 2026, covering the consolidated financial position, comprehensive income, cash flows and equity changes of the Group. The full in...
EuroEyes warns interim loss amid acquisition costs but underlying business stays firm
Aug 24, 2026
EuroEyes International Eye Clinic Limited has warned that it expects to post a loss of HK$10 million to HK$17 million for the six months ended 30 June 2026, reversing a profit of HK$38.4 million a year earlier. The board attributes the swing prima...
EuroEyes Schedules Board Meeting to Approve 2026 Interim Results and Consider Dividend
Aug 14, 2026
EuroEyes International Eye Clinic Limited has scheduled a board meeting for 31 August 2026 to review and approve the interim results for the six months ended 30 June 2026 and to consider the publication of those figures. The board will also evalua...
EuroEyes Bolsters European Push with Appointment of New Executive Director
Aug 3, 2026
EuroEyes International Eye Clinic Limited has appointed 60-year-old Rens Laurentius Michaël Schoenmakers as an executive director effective 3 August 2026, strengthening its leadership bench with a veteran of the medical devices, medtech and h...
EuroEyes clarifies board and committee roles in governance update
Aug 3, 2026
EuroEyes International Eye Clinic Limited has updated its board composition, confirming a slate of five executive directors and three independent non-executive directors effective 3 August 2026, with founder Dr. Jørn Slot Jørgensen servi...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.